Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FL2B9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $75,716
Award facts
- Contract value 100% obligated
- $75,716.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $75,716 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml syringes. The contract, issued on September 26, 2025, with an ultimate completion date of September 29, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million and extending through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.
Nucala (mepolizumab) is a monoclonal antibody biologic used primarily for treating eosinophilic asthma and other eosinophil-mediated conditions. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders for specialty medications, biologics, and medical consumables across the Department of Defense healthcare system. The company's position as a woman-owned small business and its extensive experience distributing pharmaceutical products to military health facilities has enabled it to compete effectively in federal procurement markets while maintaining a robust portfolio of high-value pharmaceutical contracts.
Quick answers
Who was awarded contract SPE2DB25FL2B9?
SPE2DB25FL2B9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FL2B9 worth?
The government has obligated $75,716 on SPE2DB25FL2B9.
Is contract SPE2DB25FL2B9 an order under another contract?
Yes. SPE2DB25FL2B9 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL2B9 competed?
The extent of competition for SPE2DB25FL2B9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award